Effect of naturally occurring α-synuclein-antibodies on toxic α-synuclein-fragments. 2019

Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
Department of Neurology, Philipps-University of Marburg, Marburg, Germany; Department of Neurology, University of Cologne, Cologne, Germany.

Alpha-synuclein (α-Syn) is a soluble protein primarily expressed in presynaptic terminals in the central nervous system (CNS). Aggregates of fibrillated α-Syn are the major component of Lewy bodies (LB), a pathologic hallmark of idiopathic Parkinson's disease (PD). Recently, naturally occurring autoantibodies against human α-Syn (nAbs α-Syn) were detected in the peripheral blood of PD patients and controls. Here, we investigated the inhibitory effects of nAbs α-Syn on distinct α-Syn fragments, as well as inflammatory responses and cytotoxicity evoked by nAbs α-Syn in primary microglia. All α-Syn fragments induced the release of the pro-inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) from microglia in primary culture. Cotreatment with nAbs α-Syn alleviated the release of pro-inflammatory cytokines induced by α-Syn fragments α-Syn 1-95, α-Syn 61-140, α-Syn 96-140 and α-Syn 112. Treatment with the α-Syn fragments α-Syn 1-95, α-Syn 61-140 and α-Syn 112 impaired the viability of primary microglia. This effect could not be counteracted by cotreatment with nAbs α-Syn. Data suggest an important role of nAbs α-Syn in the α-Syn-induced inflammation cascade, and indicate the potential importance of nAbs in the pathogenesis of PD. This could provide an experimental therapeutic target for patients with PD.

UI MeSH Term Description Entries
D008636 Mesencephalon The middle of the three primitive cerebral vesicles of the embryonic brain. Without further subdivision, midbrain develops into a short, constricted portion connecting the PONS and the DIENCEPHALON. Midbrain contains two major parts, the dorsal TECTUM MESENCEPHALI and the ventral TEGMENTUM MESENCEPHALI, housing components of auditory, visual, and other sensorimoter systems. Midbrain,Mesencephalons,Midbrains
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon

Related Publications

Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
January 2012, Advances in experimental medicine and biology,
Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
January 2013, Neurology,
Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
April 2019, Neurobiology of disease,
Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
March 2022, Biomolecules,
Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
February 2023, Neuropathology and applied neurobiology,
Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
April 1981, Critical reviews in toxicology,
Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
November 1977, Clinical pharmacology and therapeutics,
Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
January 1980, Progress in lipid research,
Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
November 1971, European journal of immunology,
Monika Rabenstein, and Daniela Besong Agbo, and Elias Wolf, and Judith Dams, and Marina Nicolai, and Andreas Roeder, and Michael Bacher, and Richard C Dodel, and Carmen Noelker
September 1977, Revue francaise de transfusion et immuno-hematologie,
Copied contents to your clipboard!